POWER THE COURSE OF FIGHTING DISEASES AND SAVING LIVES
Domain expertise, global resource, long-term capital
PORTFOLIO NEWS
Adds Novel Bio-Activated Pharmaceuticals to Glaukos’ New Corneal Health Franchise Potential...Cambridge, MA and Shanghai — July 16, 2019 — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical...FOSTER CITY, CA, and SHANGHAI, June 24th, 2019 – Terns Pharmaceuticals, Inc. today announced an...2019年6月18日Jacobio’s SHP2 inhibitor (JAB-3068) independently developed by Jacobio Pharmaceuticals Co., Ltd....2019年5月29日INDIANAPOLIS, May 28, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a...EVOTEC’S OFFERING OF INTEGRATED SOLUTIONS EXTENDED TO BIOLOGICSADDITION OF LONGSTANDING BIOLOGICS...2019年5月16日San Francisco, May 16, 2019 – Tempest Therapeutics Inc., a clinical-stage biotechnology company...BELTSVILLE, Md., May 08, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage...More Posts
Company
Shanghai
Room2909-14, 168 Hubin Road, Huangpu District, Shanghai, China.
Hong Kong
Unit 902-904, Two ChinaChem Central, 26 Des Voeux Road Central, Hong Kong
US
2730 Sand Hill Road, Suite 130, Menlo Park, CA
All Posts
×
LillyAsiaVentures
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
http://user-assets.sxlcdn.com/images/315509/FnksTvTDur7jpExbqYminmtjWgoM.png?imageMogr2/strip/auto-orient/thumbnail/1200x630>/format/png